Monograph Capital - aVenture Asset Manager Research
Location
London, Greater London, GB
Founded
2021
Monograph Capital is a transatlantic life sciences venture firm focused on investing in groundbreaking companies developing therapeutics, diagnostics, and technology-enabled healthcare services. With offices in London, San Francisco, and Dallas-Fort Worth, the firm bridges opportunities across North America, the United Kingdom, and Europe, typically investing in Series A and B rounds.
The firm leverages its deep medical expertise, long-standing pharmaceutical relationships, and seasoned operating experience to build value for portfolio companies. Notable investments include HI-Bio and Sudo Biosciences, both of which have raised over $100 million. Monograph's team combines differentiated sourcing strategies with extensive industry knowledge to transform promising science into life-changing treatments worldwide.
Monograph Capital - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies2
Current Portfolio Count2
Top Investment Stages
Series A1 (50.0%)
Series B1 (50.0%)
Stage Mix
Series A 50%Series B 50%
Concentration shown as share of disclosed investments by stage.
